The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?

Hepatology

Volumn 49, Issue 2, 2009, Pages 702-703

  Aghemo, Alessio ^a   Rumi, Maria Grazia ^a   Prati, Gian Maria ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANTIVIRAL THERAPY; CLINICAL PROTOCOL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; VIRUS STRAIN; DOSE RESPONSE; GENETICS;

DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RIBAVIRIN;

EID: 61949379759     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22732     Document Type: Letter

References (4)

1. Ferenci P, Brunner H, Laferl H, et al. A randomized, prospective trial of ribavirin 400 rag/day versus 800 rag/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008;47: 1816-1823.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-982.
3. Hadziyannis SJ, Setre H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
4. Rizzetto M. Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin. J Hepatol 2005;42:275-276.